Robotic Biopsy Devices Market: as Intuitive Surgical’s Ion endoluminal bronchoscopy procedure volume grows nearly three times faster than its core da Vinci surgical procedure base, robotic tissue sampling is proving to be a genuinely distinct growth engine from robotic resection, so device manufacturers are increasingly building biopsy-specific robotic platforms rather than treating tissue acquisition as an accessory function of a broader surgical robot, and the anatomical site of biopsy, lung, prostate, or deep percutaneous lesion, is becoming the primary axis of platform differentiation rather than robotic technology generation.

The global robotic biopsy devices market size was USD 942.0 Million in 2025 and is expected to register a revenue CAGR of 13.2% during the forecast period. Market revenue growth is driven by factors such as robotic bronchoscopy biopsy platforms achieving procedure volume growth substantially faster than the broader robotic surgery base, MRI-guided robotic prostate biopsy becoming the preferred alternative to systematic transrectal ultrasound-guided biopsy following updated clinical guidelines, and CT-guided robotic percutaneous biopsy platforms extending robot-assisted tissue sampling to liver, kidney, bone, and deep tissue lesions. The first driving factor is robotic bronchoscopy biopsy platforms, including Intuitive Surgical’s Ion and Johnson & Johnson’s Monarch, achieving procedure volume growth substantially faster than the broader robotic surgery base for peripheral pulmonary nodule tissue acquisition. Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025 compared with the fourth quarter of 2024, nearly three times the approximately 17% growth rate recorded for da Vinci surgical procedures over the same period, reflecting shape-sensing and electromagnetic navigation technology’s rapid adoption for peripheral lung lesion biopsy specifically. The second driving factor is MRI-guided in-bore robotic prostate biopsy systems becoming the preferred alternative to systematic transrectal ultrasound-guided biopsy, enabling transperineal needle placement with sub-millimetre targeting accuracy at MRI-detected PI-RADS lesions. Updated clinical guidelines from the American Urological Association and European Association of Urology increasingly favour targeted, MRI-guided biopsy approaches over systematic transrectal ultrasound-guided sampling, directly supporting robotic in-bore biopsy platform adoption for prostate cancer diagnosis. The third driving factor is CT-guided robotic percutaneous biopsy platforms extending robot-assisted needle trajectory planning and insertion to liver, kidney, bone, and deep tissue lesion sampling at interventional radiology programme accounts globally. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way robotic biopsy platform adoption for one anatomical site builds institutional procedural familiarity and infrastructure that extends more readily to adjacent biopsy applications than to unrelated robotic surgical resection, letting one interventional or pulmonology programme’s robotic biopsy investment compound across multiple tissue sampling indications within that same clinical specialty. Once an interventional radiology or pulmonology programme establishes robotic biopsy workflow, including credentialed staff and integrated imaging guidance infrastructure, for one anatomical application, extending that same procedural and technical familiarity to an adjacent biopsy indication within the same specialty requires less incremental investment than establishing an entirely new robotic surgical capability from scratch, so robotic biopsy platform adoption compounds within a clinical specialty more efficiently than it extends across unrelated specialties. As a result, demand and revenue share are concentrating around platforms with the clearest single-specialty procedural adoption pathway, whether bronchoscopy for pulmonology or in-bore biopsy for urology, and the forecast tilts toward specialty-specific robotic biopsy platform adoption rather than general-purpose robotic systems attempting to serve multiple biopsy applications simultaneously. For instance, in the fourth quarter of 2025, Ion endoluminal procedure volume grew approximately 44% while da Vinci surgical procedure volume grew approximately 17% over the same period, illustrating how a biopsy-specific robotic platform, once established within pulmonology programmes for peripheral lung lesion sampling, is compounding procedure volume faster than the broader multi-specialty surgical robotic platform it shares a parent company with. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the outsized procedure volume growth rate robotic bronchoscopy biopsy platforms are achieving relative to the broader robotic surgical resection base they are often commercially grouped alongside. Peripheral pulmonary nodule biopsy addresses a distinct clinical need, diagnostic tissue sampling rather than therapeutic resection, and this distinct clinical use case, combined with rising lung cancer screening volume identifying more early-stage nodules requiring biopsy, is what has allowed robotic bronchoscopy procedure volume to grow at a meaningfully faster rate than robotic surgical resection procedure volume, so screening-driven diagnostic demand and robotic bronchoscopy procedure growth are directly linked. Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025 compared with the fourth quarter of 2024, according to Intuitive Surgical’s reported results, compared with approximately 17% growth for da Vinci surgical procedures over the same period. The effect on the market is that robotic biopsy technology is establishing itself as a distinct, rapidly scaling growth category within robotic medicine broadly, not simply an accessory application of general-purpose surgical robotic platforms. These are some of the key factors driving revenue growth of the market.

The second driver is the shift in prostate cancer diagnostic practice toward targeted, MRI-guided biopsy approaches, supported by updated clinical society guidance favouring this technique over systematic (non-targeted) transrectal ultrasound-guided sampling. Systematic transrectal ultrasound-guided biopsy samples a predetermined grid of prostate locations regardless of where suspicious tissue is actually located, while MRI-guided in-bore robotic biopsy targets needle placement specifically at MRI-detected PI-RADS lesions with sub-millimetre accuracy, and this targeting precision advantage is what has driven updated AUA and EAU guidelines to favour targeted approaches, so guideline evolution and robotic in-bore biopsy platform adoption are directly linked. Updated clinical guidelines from the American Urological Association and European Association of Urology increasingly favour targeted, MRI-guided biopsy approaches over systematic transrectal ultrasound-guided sampling for prostate cancer diagnosis, directly supporting robotic in-bore biopsy platform adoption at urology programmes performing transperineal needle placement. The effect on the market is that robotic MRI-guided prostate biopsy adoption increasingly tracks clinical guideline evolution rather than solely individual physician or institutional preference. These are some of the key factors driving revenue growth of the market.

“Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025, nearly three times the approximately 17% growth rate recorded for da Vinci surgical procedures over the same period, confirming that robotic tissue sampling for peripheral pulmonary nodule biopsy has become a genuinely distinct and faster-growing category than robotic surgical resection.”

The third driver is the extension of robotic biopsy technology beyond bronchoscopy and prostate applications into CT-guided percutaneous sampling of liver, kidney, bone, and other deep tissue lesions. Deep tissue lesions require precise needle trajectory planning to avoid critical anatomical structures while reaching the target lesion, and robot-assisted trajectory planning and insertion technology addresses this precision requirement more consistently than freehand CT-guided technique alone, which is why interventional radiology programmes are adopting robotic percutaneous biopsy platforms specifically for the most anatomically challenging deep tissue sampling cases. CT-guided robotic percutaneous biopsy platforms deploying robot-assisted needle trajectory planning and insertion are extending robotic tissue sampling capability to liver, kidney, bone, and deep tissue lesion applications at interventional radiology programme accounts globally. The effect on the market is that robotic biopsy technology adoption is broadening beyond its original bronchoscopy and prostate application base into the wider interventional radiology practice. These are some of the key factors driving revenue growth of the market.

However, the robotic biopsy devices market faces adoption constraints from the capital cost of dedicated robotic biopsy platforms relative to conventional biopsy technique, specialised physician training requirements across each distinct anatomical application, and reimbursement and coverage variation by application and jurisdiction. Because dedicated robotic biopsy platforms, whether for bronchoscopy, in-bore prostate biopsy, or CT-guided percutaneous sampling, represent a meaningful capital investment beyond conventional freehand or ultrasound-guided biopsy technique, hospital and interventional programme budget constraints continue to influence adoption pace even as clinical evidence increasingly favours robotic approaches for specific applications, and this capital barrier concentrates robotic biopsy adoption among larger academic and tertiary interventional programmes. Specialised physician training across distinct anatomical applications is a second constraint, because robotic bronchoscopy, in-bore prostate biopsy, and CT-guided percutaneous biopsy each require their own procedural training specific to the anatomical site and guidance modality involved, and this specialty-specific training requirement limits how quickly a single interventional programme can build competency across multiple robotic biopsy applications simultaneously, meaning most programmes adopt robotic biopsy technology for one anatomical application before expanding to others. Reimbursement and coverage variation by application is the third constraint, since robotic biopsy reimbursement varies meaningfully by anatomical application and jurisdiction, and newer applications such as CT-guided robotic percutaneous biopsy face a less established coverage pathway than more clinically established applications such as robotic bronchoscopy, meaning realised adoption pace across different biopsy applications does not track clinical evidence quality uniformly. These factors substantially limit robotic biopsy devices market growth over the forecast period.

Based on product type, the global robotic biopsy devices market is segmented into robotic bronchoscopy systems, robotic prostate biopsy systems, and robotic percutaneous biopsy systems. Robotic bronchoscopy systems hold the largest revenue share, because they represent the most commercially mature robotic biopsy platform category with the longest track record of clinical adoption, which suits Intuitive Surgical’s and Johnson & Johnson’s established Ion and Monarch platforms. Robotic percutaneous biopsy systems are expected to register the fastest revenue growth rate in the global robotic biopsy devices market over the forecast period, driven by extending robotic trajectory planning technology into liver, kidney, bone, and deep tissue applications, which is why this category represents the newest frontier of robotic biopsy platform expansion.

Peripheral pulmonary nodule sampling application is expected to account for a significantly large revenue share in the global robotic biopsy devices market during the forecast period

Based on application, the global robotic biopsy devices market is segmented into peripheral pulmonary nodule sampling, prostate cancer diagnosis, and liver, kidney, bone, and deep tissue lesion sampling. Peripheral pulmonary nodule sampling holds a significant revenue share, reflecting robotic bronchoscopy’s established clinical adoption and its direct link to expanding lung cancer screening programme volume identifying more nodules requiring biopsy. Prostate cancer diagnosis is expected to register rapid revenue growth in the global robotic biopsy devices market over the forecast period, driven directly by updated AUA and EAU clinical guidelines favouring targeted, MRI-guided biopsy approaches, which is why this application represents one of the fastest-evolving areas of robotic biopsy adoption.

Shape-sensing/electromagnetic navigation guidance is expected to account for the largest revenue share in the global robotic biopsy devices market during the forecast period

Based on imaging guidance, the global robotic biopsy devices market is segmented into shape-sensing/electromagnetic navigation, MRI-guided in-bore, and CT-guided guidance modalities. Shape-sensing/electromagnetic navigation holds the largest revenue share, reflecting its established role in robotic bronchoscopy platforms navigating the branching anatomy of the peripheral bronchial tree to reach pulmonary nodules. MRI-guided in-bore guidance is expected to register rapid revenue growth in the global robotic biopsy devices market over the forecast period, driven directly by updated prostate biopsy clinical guidelines, which is why this guidance modality represents a fast-growing category tied specifically to prostate cancer diagnostic practice evolution.

Based on regional analysis, the robotic biopsy devices market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of lung cancer screening programmes and interventional radiology infrastructure, and because Intuitive Surgical and Johnson & Johnson both concentrate significant commercial and clinical development activity in the country. The American Urological Association’s updated prostate biopsy guidelines, favouring targeted MRI-guided approaches, directly shape United States urology practice and robotic in-bore biopsy platform adoption specifically. The concentration of leading robotic biopsy platform manufacturers and lung cancer screening infrastructure in the United States also means new robotic biopsy technology is typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national robotic biopsy devices markets within Europe. The European Association of Urology’s updated prostate biopsy guidelines parallel AUA guidance in favouring targeted MRI-guided approaches, and the region’s established interventional radiology infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature interventional infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national robotic biopsy devices markets within the region. Expanding lung cancer screening programme investment and rising interventional radiology infrastructure investment in China are driving new robotic biopsy demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national robotic biopsy devices markets within the region. Academic interventional radiology and urology programmes in both countries are gradually adopting robotic biopsy technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised robotic biopsy platforms that Latin American academic centres depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial robotic biopsy devices markets within the GCC. The UAE is the most established robotic biopsy devices market on the continent given its concentrated private hospital interventional infrastructure, while the wider Gulf states and broader African markets are still building the specialist interventional radiology and pulmonology capacity that robotic biopsy adoption depends on.